GEN-Thermo_Oct22_MakingThePromiseOf - 7

OVERCOMING mRNA PRODUCTION SCALE-UP CHALLENGES
body. These cells shed DNA into the bloodstream,
which can help researchers identify if
the patient is at high risk for recurring colorectal
cancer [6]. Now a clinical trial is following highrisk
patients with stage II and stage III colorectal
cancer who test positive for circulating tumor
DNA after surgery [7]. Lastly, clinical leaders
are also exploring the potential of mRNA for
producing proteins missing in many diseases,
such as cystic fibrosis, diabetes, and sickle cell
anemia [8].
As mRNA-based therapeutics continue to
garner increased interest, it is also important to
remember key lessons the pandemic has taught
us: collaboration and partnership are critical to
problem solving. The biotech industry is ushering
the world into a new era where the ways in which
clinicians care for their patients may more closely
align with what's very important: high-quality,
accessible, and equitable treatments.
References
1. Dolgin E (2001) The tangled history of mRNA vaccines. Nature
597(7876):318-324.
2. Karikó K, Buckstein M et. al. (2005) Suppression of RNA
recognition by Toll-like receptors: the impact of nucleoside
modification and the evolutionary origin of RNA. Immunity
23(2):165-175.
3. https://www.news-medical.net/news/20210203/Phase-1-clinical-trial-of-novel-HIV-vaccine-approach-shows-promisingresults.aspx
4.
https://www.who.int/data/gho/data/themes/hiv-aids
5. https://www.cdc.gov/nchhstp/newsroom/fact-sheets/hiv/
state-of-the-hiv-epidemic-factsheet.html
6. Cheng F, Su L, Qian C (2016) Circulating tumor DNA: a promising
biomarker in the liquid biopsy of cancer. Oncotarget
7(30):48832-48841.
7. https://clinicaltrials.gov/ct2/show/NCT04486378
8. Qin, S, Tang, X et al. (2022) mRNA-based therapeutics:
powerful and versatile tools to combat diseases. Sig Transduct
Target Ther 7(1):166-200.
© 2022 Thermo Fisher Scientific Inc. All rights reserved. All
trademarks are the property of Thermo Fisher Scientific and its
subsidiaries unless otherwise specified. ProQuad and RotaTeq are
trademarks of Merck & Co., Inc. Avaxim and Fluzone are trademarks
of Sanofi Pasteur Limited. FluLava is a trademark of GSK plc. Fluad is
a trademark of Seqirus UK Limited. EXT3856 1022
mRNA Production: Raw Material Inputs Matter
Accelerate mRNA vaccine and
therapeutics production from pre-clinical
development to commercialization with
a comprehensive product portfolio of
GMP-grade raw materials that meet critical
process, scale, quality, and regulatory
needs.
Find The Resources
GENengnews.com | 7

https://www.thermofisher.com/us/en/home.html https://www.news-medical.net/news/20210203/Phase-1-clinical-trial-of-novel-HIV-vaccine-approach-shows-promising-results.aspx https://www.news-medical.net/news/20210203/Phase-1-clinical-trial-of-novel-HIV-vaccine-approach-shows-promising-results.aspx https://www.news-medical.net/news/20210203/Phase-1-clinical-trial-of-novel-HIV-vaccine-approach-shows-promising-results.aspx https://www.who.int/data/gho/data/themes/hiv-aids https://www.cdc.gov/nchhstp/newsroom/fact-sheets/hiv/state-of-the-hiv-epidemic-factsheet.html https://www.cdc.gov/nchhstp/newsroom/fact-sheets/hiv/state-of-the-hiv-epidemic-factsheet.html https://clinicaltrials.gov/ct2/show/NCT04486378 https://www.thermofisher.com/us/en/home/industrial/pharma-biopharma/nucleic-acid-therapeutic-development-solutions/mrna-therapeutic-resources/mrna-synthesis-reagents.html?cid=bid_nat_mrw_r01_co_cp1531_pjt9473_ext3856_0db_gbn_eb_tls_an_s00_ https://www.genengnews.com

GEN-Thermo_Oct22_MakingThePromiseOf

Table of Contents for the Digital Edition of GEN-Thermo_Oct22_MakingThePromiseOf